(Adnkronos) - “Lo studio Echo ha portato risultati molto soddisfacenti: la terapia innovativa associata a chemioimmunoterapia con acalabrutinib ha dimostrato un miglioramento nei pazienti con linfoma mantellare in prima linea, quindi non precedentemente trattati, nella progressione libera da malattia e con un forte trend anche nei confronti di sopravvivenza globale. Quindi questa associazione, risultata anche poco tossica rispetto a quanto poteva essere atteso da una simile combinazione di più farmaci, diventerà un nuovo standard di terapia nei linfomi mantellari nei pazienti con 65 anni o oltre, quindi adulti e anziani, e rappresenterà uno step ulteriore nel miglioramento della sopravvivenza globale di questa importante patologia ematologica”. A dirlo, Carlo Visco, professore di ematologia e coordinatore dell’unità Linfomi all’università di Verona, in occasione della conferenza stampa dedicata alla presentazione dei risultati dello studio Echo su acalabrutinib in combinazione con chemio-immunoterapia nel trattamento di prima linea di pazienti over 65 con linfoma mantellare.
Category
🗞
NewsTranscript
00:00Lymphoma mantellare represents about 6% of non-Hodgkin lymphomas,
00:10so it is a rare form of lymphoma that is an age of insurgency that occurs in the adult-old age,
00:19so an average of about 65 years.
00:23The disease is characterized by an heterogeneous presentation,
00:29so it can appear with very aggressive forms from a clinical point of view
00:35up to rather painful forms, so it is very heterogeneous,
00:40there is no rule for clinical presentation,
00:43even if in reality most of the pathologies occur with a thickening of the lymph nodal glands,
00:50like all Hodgkin and non-Hodgkin lymphomas.
00:54Lymphoma mantellare has been studied a lot in the past by researchers and doctors from all over the world
01:03because it represented for a long time the non-Hodgkin lymphoma with the worst prognosis.
01:09The average survival, about 20 years ago, was 3 years of a patient who got sick with this disease.
01:16Now, in the last 10-15 years, thanks to scientific research,
01:20a clear improvement of this prognosis has been observed,
01:23with an average survival that is more than doubled
01:26and a life expectancy that is therefore much improved for our patients with this pathology.
01:32Also thanks to the commitment of the Italian Foundation of Lymphoma, the FIL,
01:37which has worked for research in lymphoma mantellare not only in Italy,
01:43giving significant contributions to global research.
01:47At the beginning of this year, at the congress that just took place in San Diego, California,
01:55about 30,000 delegates from all over the world were present.
01:59So you understand the importance of this meeting for the exchange of ideas and research
02:05that take place globally in lymphomas and not only in all hematological neoplasies.
02:11In particular, the ECHO study was presented.
02:15The ECHO study is a randomized phase 3 study with double blindness versus placebo,
02:22which compared standard therapy,
02:24i.e. R-bendamostine with maintenance reduction plus placebo,
02:29versus an innovative therapy, always based on R-bendamostine plus R,
02:35but instead of placebo there was Calabrutinib,
02:37i.e. an inhibitor of the BTK enzyme,
02:40which represents a very effective targeted therapy,
02:44known to be very effective in this pathology.
02:47The study has brought very satisfactory results,
02:52in the sense that the innovative therapy associated with immunotherapy, with Calabrutinib,
02:58has shown improvement in patients in the first place,
03:03therefore not previously treated,
03:05both in the free progression of the disease
03:08and with a strong trend also in relation to global survival.
03:13So this association, which has also been little toxic
03:17compared to what could have been expected from a similar combination of several drugs,
03:23will possibly become a new standard of therapy in mammary lymphomas
03:31at the age of 65 or older, i.e. elderly adults,
03:35and will represent a further step in the improvement of global survival
03:42in this important hematological pathology.